罗格列酮对2型糖尿病肾病患者血清C反应蛋白的影响

Effect of Rosiglitazone in type 2 diabetic nephropathy patients with C reactive protein

目的：观察罗格列酮治疗糖尿病肾病前后血清C反应蛋白（CRP）的变化及其影响因素,探讨炎症因子与糖尿病肾病的关系。方法：将56例2型糖尿病肾病受试者随机分为罗格列酮治疗组（RSG组）和卡托普利治疗组（ACEI组）,分别应用RSG（4 mg/d）及卡托普利（25－50 mg/d）治疗12周,观察治疗前后C反应蛋白水平的变化。结果：1.罗格列酮治疗前后CRP（6.81±1.73 mg/L vs 2.46±0.65 mg/L;P〈0.05）差异有统计学意义。2.RSG组CRP（2.46±0.65 mg/L vs 3.96±1.00 mg/L;P〈0.05）及UAlb/Cre（28.22±1.65μg/mg vs 37.83±2.73μg/mg;P〈0.05）的改善明显优于对照组。3.RSG组CRP与FPG、2hPG、空腹C肽、HbA1C、UAlb/Cre均有正相关关系（P〈0.01）。结论：罗格列酮治疗早期糖尿病肾病在降低炎症反应以致最终减少尿微量蛋白方面可能优于卡托普利。

Objective：Observe the change of serum C-reactive protein（CRP） before and after rosiglitazone treatment of diabetic nephropathy,and investigate the relationship between inflammatory factors and diabetic nephropathy.Methods： 56 patients with type 2 diabetic nephropathy subjects were randomly divided into treatment groups of rosiglitazone（RSG group） and captopril treatment group（ACEI group）,were applied RSG（4 mg/d） and captopril（25-50 mg/d） for 12 weeks,and observed CRP level changes before and after treatment.Results： 1.CRP is significantly different before and after treatment with rosiglitazone（6.81±1.73 mg/L vs 2.46±0.65 mg/L;P〈0.05）.2.RSG group CRP（2.46±0.65 mg/L vs 3.96±1.00 mg/L;P〈0.05） and UAlb/Cre（28.22±1.65 μg/mg vs 37.83±2.73 μg/mg;P〈0.05） improved significantly than the control group.3.RSG group CRP and FPG,2hPG,fasting C peptide,HbA1C,UAlb/Cre were positively correlated（P〈0.01）.Conclusion： Rosiglitazone treatment of early diabetic nephropathy in reducing inflammation and eventually to reduce urinary protein is superior than captopril possibly.